The pandemic provided the best and worst of times for smid-cap medtechs.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
The UK ortho and woundcare group might yet pounce on Nuvasive.